Treprostinil, a prostacyclin vasodilator, is indicated for pulmonary arterial hypertension (PAH) (WHO Group 1) to reduce symptoms associated with exercise. It is also approved to reduce the rate of clinical deterioration in PAH patients who need to switch from epoprostenol sodium (Flolan).
The major mechanism of action involves direct vasodilation of pulmonary and systemic arterial vascular beds, and inhibition of platelet aggregation.
Treprostinil Injection will be supplied as 20mL multi-dose vials in 1mg/mL, 2.5mg/mL, 5mg/mL or 10mg/mL strengths. The product will be commercialized in collaboration with RareGen, LLC.
For more information call (609) 627-8500 or visit Sandoz.com.
This article originally appeared on MPR